advanced medical technologies - Latest Comments

Re: Global wound care market segmentation, drivers

pdriscoll — Sun, 15 Jul 2012 12:57:44 -0000

The potential market for your product is dictated by, and should be assessed against, all other competitive products for the specific applications. At the outset, it appears that your product has both a consumer and a professional or clinically oriented set of opportunities. You will likely have a very hard time finding a comprehensive analysis from a financial perspective of both the consumer and the professional segments, since they have completely different modes of distribution, market dynamics and other influences. For the professional sector, I suggest you seriously consider our report on the Worldwide Wound Management Market (see our previously published edition, #S247, at http://www.mediligence.com/..., or our forthcoming report, #S249, at http://www.mediligence.com/....

Re: Global wound care market segmentation, drivers

Robert — Sun, 15 Jul 2012 12:43:03 -0000

I have a new product that offers many different applications in the wound care market. From a cleanser to a topical spray used on cuts and scrapes. Since it is all natural it can be sprayed right on infected sites, post surgically and would be great for home usage. My product comes in 2 different formats - with silver and without, both are liquid spray applicators. My question is where can I find the most comprehensive data available that represents the potential wound care market from a financial perspective?

Robert McCoskey
robert@statventures.net

Re: The Rapidly Evolving Obesity Treatment Market

pdriscoll — Fri, 22 Jun 2012 13:10:06 -0000

Of course, one key driver behind the anticipated change in the obesity treatment landscape is the FDA's change of heart regarding obesity drugs, such as Arena Pharmaceutical's Lorcaserin, which may well receive FDA approval this month (June 2012).

Re: Treatments for Vertebral Compression Fractures

Katiflores — Wed, 30 May 2012 10:57:04 -0000

Thanks, if I find more products I will send those to you
Your list have been very useful for me
Thanks again!

Re: Treatments for Vertebral Compression Fractures

pdriscoll — Tue, 29 May 2012 15:10:32 -0000

It appears that these products were approved in late 2011. If so, yes, they should be added. As for whether there should be additional ones, I would have to do the research to determine that, but they would most likely be recent approvals, since our list was comprehensive in mid 2011.

Re: Treatments for Vertebral Compression Fractures

Katiflores — Tue, 29 May 2012 13:28:52 -0000

Hi Patrick
I found these two products:

SYNTHES / VBB System / 121311:
http://www.accessdata.fda.g...

Soteira / Shield Kyphoplasty System / 120811:
http://www.accessdata.fda.g...

I am adding those products to the Kyphoplasty list
What do you think?

Do you know about other products that I can be missing and are not in your list yet?

Thanks!

Re: Wound prevalence and healing times

pdriscoll — Tue, 29 May 2012 12:26:23 -0000

These are 2011 figures based on a wide range of data sources. We are also in the process of completing our 2012 analysis for our Worldwide Wound Report #S249 (http://mediligence.com/rpt/... and expect to confirm this data with nominal changes arising from trends.

Re: Wound prevalence and healing times

Maria — Tue, 29 May 2012 11:51:33 -0000

I would appreciate whether you could clarify my doubts about this data. Does this prevalence refer to 2011? I was wondering if it's an estimate for 2017 or the current values of wound prevalence. Thank you very much.

Re: Treatments for Vertebral Compression Fractures

Katiflores — Fri, 18 May 2012 10:46:54 -0000

I see it!
THANKS!

Re: Treatments for Vertebral Compression Fractures

pdriscoll — Thu, 17 May 2012 18:03:35 -0000

Katiflores:

We did a few upgrades on WordPress and it apparently affected the display of tables, but that has now been corrected. Let me know if you don't see the table above now.

Patrick

Re: Treatments for Vertebral Compression Fractures

Katiflores — Thu, 17 May 2012 16:52:16 -0000

Hi,
Is there any chance that you can upload again the table, because I can not see it.
Thanks!

Re: Current clinical applications in tissue engineering and cell therapy

Ivan djordjevic — Tue, 15 May 2012 02:13:16 -0000

yeah sure thing, in particular nerve tissue engineering is more like a science fiction than the accurate science. this report is way too optimistic.

Re: Spine surgery segments distinguished by size and growth

pdriscoll — Wed, 09 May 2012 16:55:34 -0000

For any Stephen Wright aficionados out there, you may know that his actual quote was, "by the time I'm 6, I'll be 90." I simply did him the benefit of correcting his math. Doubling each year from 1 to 6 would indeed be 32, not 90.

Re: Tissue engineering and cell therapy market

pdriscoll — Sun, 06 May 2012 13:56:51 -0000

The graphic is in this article. If you are unable to see it, you may go directly to http://mediligence.com/blog....

Re: Tissue engineering and cell therapy market

Minshuli2012 — Sun, 06 May 2012 01:42:41 -0000

I need to see the graf , thank you

Re: Factors Affecting Wound Healing

Kate_mcblanch — Sat, 21 Apr 2012 00:03:30 -0000

Very helpful information for diploma of nursing. Thanks!

Re: Wound prevalence and healing times

pdriscoll — Wed, 21 Mar 2012 09:33:32 -0000

Prevalence is a total current number for any given condition, while incidence is a rate over time, so the 7-8M/year is incidence and the 40M worldwide is prevalence. Therefore, if indeed the incidence figure for Medicare and Medicard is 7-8M in the U.S. per year, then a worldwide prevalence of 40M is completely within the expected range.

Re: Wound prevalence and healing times

ButterFlyMonkey1 — Tue, 20 Mar 2012 23:11:25 -0000

If US Medicare and Medicaid is reporting 7-8M as the prevalence of chronic wounds per year, how is your worldwide estimation only 40M? How did you estimate the prevalence of the 6.8B+ people, or is just a subset of the world?

Re: New medical technology startups identified in February 2012

pdriscoll — Fri, 16 Mar 2012 11:32:28 -0000

Sickle cell is an inherited disease resulting from a person receiving genes from both parents for an abnormally formed hemoglobin, which distorts the shape of the red blood cell and causes them to not flow normally in the blood stream. (People who receive a normal hemoglobin gene from one parent and a sickle cell gene from the other parent have what is called "sickle cell trait", resulting in few complications for most patients.)
Because sickle cell is an inherited disease, it can only be "cured", in principle, by replacing the defective genes. Medical science is working aggressively in this direction, but this remains a big technology hurdle, given the complexity needed to achieve it. For the time being, treatments for sickle cell can at best be accomplished with bone marrow transplant (creating a "factory" in bone marrow to produce red blood cells with normal hemoglobin). Otherwise, a wide variety of options are available to help sickle cell patients deal with the complications.

Re: New medical technology startups identified in February 2012

michael — Fri, 16 Mar 2012 05:37:13 -0000

why is there no medicine apart from bone marrow transplant to cure sickle cell disease

Re: Gecko feet, mussel shells and other sticky things

pdriscoll — Wed, 14 Mar 2012 15:10:44 -0000

From a slightly different perspective, Univ. of Massachusetts Amherst researchers have examined the roles of gecko tendons and bones in adhesiveness. http://www.physorg.com/news....

Re: Wound prevalence and healing times

pdriscoll — Thu, 01 Mar 2012 17:45:52 -0000

The healing time of 40 days for chronic wounds is generous at best. Many chronic wounds (decubitus, stasis, and diabetic ulcers) have such extended wound healing times that most estimates leave "healing time" blank. The purpose in putting in "40 days" in the above graph was to simply get the prevalence number to be shown on the graph.

Re: Advanced wound care technologies

pdriscoll — Mon, 27 Feb 2012 09:28:39 -0000

Abhilasha:

Please email your request to patrick AT mediligence DOT com

Re: Advanced wound care technologies

Abhilasha — Mon, 27 Feb 2012 06:20:42 -0000

Hello,

I want to publish the above said graph in our non-profit news letter i.e. Nanotech Insight in India. Please let me know if I can do it.

Best,

Abhilasha Verma

Re: Degenerative disc diseases, implications for spinal surgery technolologies

Kencoach1202 — Thu, 19 Jan 2012 09:58:19 -0000

The other type of back and leg pain is chronic, lasting for more than two months.
There are two generations of back disc symptoms and leg pain. One is acute or short term back and leg pain which usualy last from periods of a few days to a few weeks.